Juliana Fittipaldi
Research Subjects
Research Interests
Juliana Fittipaldi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
1 shared publication - Cristiane Fonseca De Almeida
Evandro Chagas National Institute of Infectious Diseases (INI) Oswaldo Cruz Foundation (FIOCRUZ) Rio de Janeiro Brazil
1 shared publication - Estevão Portela Nunes
Evandro Chagas Infectious Diseases National Institute Oswaldo Cruz Foundation Rio de Janeiro Brazil
1 shared publication - Hugo Perazzo
Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil
1 shared publication - Patricia Dias de Brito
Fundação Oswaldo Cruz
1 shared publication - Sandra Wagner Cardoso
Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 July 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (10) , 1525-1539
Metabolic dysfunction‐associated liver disease predicts incident liver fibrosis in people with HIV mono‐infection: A cohort study
Introduction: Metabolic dysfunction‐associated liver disease (MASLD) might progress to cirrhosis. We aimed to evaluate the association of MASLD with the risk of developing clinically significant fibrosis (CSF) in people living with HIV (PLWH). Methods: PLWH have been followed up since 2015 in the PROSPEC‐HIV cohort (NCT02542020) with questionnaires, blood samples, and transient elastography (TE) on the same day. Participants with viral hepatitis, who were c‐ART naïve, those with CSF at baseline or unreliable TE examinations and who lost follow‐up were excluded. Liver steatosis and fibrosis were assessed by TE‐Controlled Attenuation Parameter (CAP) and TE‐liver stiffness measurement (LSM), respectively. MASLD was defined as the presence of steatosis (CAP ≥263 dB/m) at baseline with at least one cardiometabolic risk factor without hazardous alcohol intake [Alcohol Use Disorders Identification Test (AUDIT) score 2 and 17.8% with MASLD) were included. During a median follow‐up of 7.4 (IQR, 6.0–8.3) years, 11.8% ( n = 36) participants developed CSF. The cumulative incidence of CSF at the 8th year was higher in PLWH with MASLD than in those without (30.1% [95% CI, 18.0–47.6] vs. 8.8% [95% CI, 5.4–14.2], p < 0.001). MASLD at baseline was significantly associated with the incidence of CSF in a multivariate Cox model (adjusted hazard ratio [aHR] = 2.92 [95% CI, 1.40–6.09]). Conclusion: MASLD increased the risk of liver fibrosis in people with HIV mono‐infection under c‐ART.
- 23 July 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (10) , 1525-1539
Open AccessMetabolic dysfunction‐associated liver disease predicts incident liver fibrosis in people with HIV mono‐infection: A cohort study
Introduction: Metabolic dysfunction‐associated liver disease (MASLD) might progress to cirrhosis. We aimed to evaluate the association of MASLD with the risk of developing clinically significant fibrosis (CSF) in people living with HIV (PLWH). Methods: PLWH have been followed up since 2015 in the PROSPEC‐HIV cohort (NCT02542020) with questionnaires, blood samples, and transient elastography (TE) on the same day. Participants with viral hepatitis, who were c‐ART naïve, those with CSF at baseline or unreliable TE examinations and who lost follow‐up were excluded. Liver steatosis and fibrosis were assessed by TE‐Controlled Attenuation Parameter (CAP) and TE‐liver stiffness measurement (LSM), respectively. MASLD was defined as the presence of steatosis (CAP ≥263 dB/m) at baseline with at least one cardiometabolic risk factor without hazardous alcohol intake [Alcohol Use Disorders Identification Test (AUDIT) score 2 and 17.8% with MASLD) were included. During a median follow‐up of 7.4 (IQR, 6.0–8.3) years, 11.8% ( n = 36) participants developed CSF. The cumulative incidence of CSF at the 8th year was higher in PLWH with MASLD than in those without (30.1% [95% CI, 18.0–47.6] vs. 8.8% [95% CI, 5.4–14.2], p < 0.001). MASLD at baseline was significantly associated with the incidence of CSF in a multivariate Cox model (adjusted hazard ratio [aHR] = 2.92 [95% CI, 1.40–6.09]). Conclusion: MASLD increased the risk of liver fibrosis in people with HIV mono‐infection under c‐ART.